LIVN
LivaNova PLC
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Last price
78.74
▲ 0.53 (0.68%)
MARKET · —
Price
Open
79.26
Prev close
78.21
Day high
79.56
Day low
77.94
Volume
419.78K
Market cap
$4.33B
P/E (TTM)
23.23
52W range
48.82 – 85.76
Trailing performance
Returnvs SPY
1W
-4.23%
-2.9%
1M
+0.17%
-3.6%
3M
+6.93%
+3.8%
6M
+15.08%
+4.0%
YTD
+27.97%
+15.7%
1Y
+47.48%
+27.5%
3Y
+43.29%
-30.9%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$4.33B
Enterprise value$4.17B
Revenue (TTM)$1.47B
Gross profit$1.00B
EBITDA$267.84M
Net income$188.55M
EPS (TTM)$3.39
Free cash flow$64.69M
Total cash$516.62M
Total debt$351.95M
Book value / share$24.07
Shares outstanding54.93M
Float54.83M
Short % of float8.64%
Dividend yield—
Beta (5Y)0.87
Valuation & profitability ratios
Trailing P/E23.23
Forward P/E16.84
PEG ratio0.93
Price / sales—
Price / book3.27
EV / revenue2.84
EV / EBITDA15.58
Gross margin68.27%
Operating margin15.52%
Profit margin12.81%
Return on equity15.40%
Return on assets5.23%
Debt / equity26.56
Current ratio1.45
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $1.39B | $1.25B | $1.15B | $1.02B |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | -$242.50M | $63.20M | $17.50M | -$86.20M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | -$242.50M | $63.20M | $17.50M | -$86.20M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 1.09 | 1.26 | +15.1% |
| Mar 2026 | 0.90 | 0.98 | +9.3% |
| Dec 2025 | 0.81 | 0.86 | +5.6% |
| Sep 2025 | 0.92 | 1.11 | +20.4% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 1.06 | 9 | $381.10M | +6.5% |
| Next quarter | 1.06 | 9 | $390.26M | +8.1% |
| Current year | 4.36 | 9 | $1.52B | +9.6% |
| Next year | 4.68 | 9 | $1.63B | +7.1% |
Analyst targets & ownership
Mean target$88.80
High target$100.00
Low target$75.00
Implied upside12.78%
Analyst count10
ConsensusBUY
Strong buy / Buy2 / 6
Hold2
Sell / Strong sell0 / 0
Held by insiders0.42%
Held by institutions113.18%
Institutions holding454
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
+131.33K
Net buying
Buy transactions
18
137.00K shares
Sell transactions
3
5.67K shares
Net transactions
+21
Buys less sells
Sell : buy shares
0.0 : 1
Mixed
Insider-held shares
229.74K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 11, 26 | TEZEL AHMET Officer |
SELL | 2.67K | $207.94K | Direct |
| Aug 11, 26 | TEZEL AHMET Officer |
CONVERSION | 12.69K | $668.62K | Direct |
| Jun 15, 26 | BIANCHI FRANCESCO Director |
SELL | 1.20K | $96.23K | Direct |
| Jun 15, 26 | BIANCHI FRANCESCO Director |
— | 4.04K | — | Direct |
| Jun 15, 26 | PODLOGAR SUSAN M Director |
— | 4.04K | — | Direct |
| Jun 15, 26 | BARRY JAMES CHRISTOPHER Director |
— | 4.04K | — | Direct |
| Jun 15, 26 | KOZY WILLIAM A Director |
— | 5.68K | — | Direct |
| Jun 15, 26 | SCHERMERHORN TODD C Director |
— | 4.04K | — | Direct |
| Jun 15, 26 | WILVER PETER M Director |
— | 4.04K | — | Direct |
| Jun 15, 26 | ENXING SENG STACY Director |
— | 4.04K | — | Direct |
| Jun 15, 26 | ZURBAY DONALD J Director |
— | 2.56K | — | Direct |
| Jun 15, 26 | STORY BROOKE Director |
— | 4.04K | — | Direct |
| Jun 15, 26 | TEZEL AHMET Officer |
— | 2.96K | — | Direct |
| May 26, 26 | BIANCHI FRANCESCO Director |
SELL | 1.80K | $136.35K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BOLTON STEPHANIE |
Officer | 22.19K | Conversion of Exercise of derivative security |
ENXING SENG STACY |
Director | 15.31K | Conversion of Exercise of derivative security |
KOZY WILLIAM A |
Director | 37.57K | Conversion of Exercise of derivative security |
MAKATSARIA VLADIMIR A. |
Chief Executive Officer | 14.17K | Conversion of Exercise of derivative security |
O'KANE SHARON |
Director | 11.30K | Conversion of Exercise of derivative security |
POLETTI FRANCO |
Officer | 10.97K | Conversion of Exercise of derivative security |
SCHERMERHORN TODD C |
Director | 12.62K | Conversion of Exercise of derivative security |
SHVARTSBURG ALEX |
Chief Financial Officer | 44.65K | Conversion of Exercise of derivative security |
STORY BROOKE |
Director | 9.79K | Conversion of Exercise of derivative security |
WILVER PETER M |
Director | 10.29K | Conversion of Exercise of derivative security |
Moving averages & technicals
SMA 10
79.94
-1.50% from price
SMA 20
80.13
-1.74% from price
SMA 50
80.49
-2.18% from price
SMA 100
74.30
+5.98% from price
SMA 200
68.42
+15.09% from price
EMA 12
79.82
-1.35% from price
EMA 26
79.89
-1.44% from price
EMA 50
78.82
-0.11% from price
RSI (14)
47.0
Neutral
MACD (12,26,9)
-0.07
Hist -0.13
ATR (14)
3.11
3.95% of price
Realised vol 30D
40.9%
Annualised
Bollinger upper
84.82
20, 2σ
Bollinger lower
75.44
20, 2σ
50 / 200 cross
Golden
80.49 vs 68.42
Trend bias
Above 200
+15.09%
Risk profile
Beta vs SPY
1.05
More volatile than market
Correlation to SPY
0.36
Loosely linked
Realised vol 30D
40.9%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-18.9%
Peak to trough
Max drawdown 5Y
-63.5%
Peak to trough
ATR 14
3.11
3.95% of price
Beta (reported)
0.87
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
4.00
Put-heavy session
Put / call open interest
1.16
Positioning, not flow
Max pain
80.00
+1.6% from spot
ATM implied vol
40.4%
Nearest strike to spot
Skew (10% OTM)
+0.7%
Puts bid over calls
Call volume
1
Contracts, this expiry
Put volume
4
Contracts, this expiry
Heaviest call OI
85.00
17 contracts
Heaviest put OI
80.00
19 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Stronger Q2 Results And New Supply Deal Might Change The Case For Investing In LivaNova (LIVN)
Simply Wall St. · 10d ago
LivaNova (LIVN) Could Be 5% Undervalued Following Raised 2026 Guidance
Simply Wall St. · 10d ago
LivaNova (LIVN) Q2 2026 Earnings Call Transcript
Motley Fool · 10d ago
LivaNova Q2 Earnings & Revenues Beat Estimates, '26 Outlook Raised
Zacks · 16d ago
LivaNova PLC Q2 2026 Earnings Call Summary
Moby · 17d ago
LivaNova PLC (LIVN) (Q2 2026) Earnings Call Highlights: Record Revenue and EPS, Raised Guidance ...
GuruFocus.com · 17d ago
LivaNova Q2 Earnings Call Highlights
MarketBeat · 17d ago
LivaNova (LIVN) Reports Q2 Earnings: What Key Metrics Have to Say
Zacks · 17d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.